
Sign up to save your podcasts
Or
Lead Story:
Naloxone Use in Novel Potent Opioid and Fentanyl Overdoses in Emergency Department Patients
JAMA Network Open
In this cohort study of 537 patients, all patients with novel potent opioid (NPO) overdose presented with opioid overdose symptoms and received multiple doses of naloxone. Compared with fentanyl overdose, patients with NPO overdose had a higher number of naloxone doses administered in-hospital; metonitazene overdose was associated with cardiac arrest and more naloxone doses overall. These findings suggest that NPOs may have a higher potency than fentanyl due to the observed naloxone administration in the clinical setting of overdose.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
4.9
77 ratings
Lead Story:
Naloxone Use in Novel Potent Opioid and Fentanyl Overdoses in Emergency Department Patients
JAMA Network Open
In this cohort study of 537 patients, all patients with novel potent opioid (NPO) overdose presented with opioid overdose symptoms and received multiple doses of naloxone. Compared with fentanyl overdose, patients with NPO overdose had a higher number of naloxone doses administered in-hospital; metonitazene overdose was associated with cardiac arrest and more naloxone doses overall. These findings suggest that NPOs may have a higher potency than fentanyl due to the observed naloxone administration in the clinical setting of overdose.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
131 Listeners
481 Listeners
687 Listeners
254 Listeners
2,413 Listeners
3,330 Listeners
1,095 Listeners
28 Listeners
282 Listeners
553 Listeners
362 Listeners
116 Listeners
31 Listeners
109 Listeners